Dna X (SONM) Common Equity (2018 - 2026)

Dna X's Common Equity history runs 9 years deep, the most recent figure standing at -$983000.0 for Q1 2026.

• Quarterly Common Equity rose 8.9% year-over-year to -$983000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$983000.0 (up 8.9% YoY) and the FY2025 annual result came in at -$8.0 million, down 39.56% from the prior year.
• Common Equity was -$983000.0 for Q1 2026 at Dna X, up from -$8.0 million in the prior quarter.
• Across five years, Common Equity topped out at $23.1 million in Q3 2023 and bottomed at -$8.0 million in Q4 2025.
• A 5-year average of $10.7 million and a median of $15.3 million in 2024 frame the typical range for Common Equity.
• Annual changes were most pronounced in 2023 — Common Equity jumped 208.74% — and 2024, when it plunged 125.48%.
• Dna X's Common Equity stood at $20.0 million in 2022, then gained by 11.59% to $22.4 million in 2023, then tumbled by 125.48% to -$5.7 million in 2024, then slumped by 39.56% to -$8.0 million in 2025, then surged by 87.64% to -$983000.0 in 2026.
• Business Quant data shows SONM's Common Equity at -$983000.0 in Q1 2026, -$8.0 million in Q4 2025, and -$701000.0 in Q3 2025.